vs
Healthpeak Properties（DOC）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是Healthpeak Properties的2.0倍（$1.4B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 27.6%，领先45.6%），瑞思迈同比增速更快（11.0% vs 3.1%），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 7.8%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
DOC vs RMD — 直观对比
营收规模更大
RMD
是对方的2.0倍
$719.4M
营收增速更快
RMD
高出7.9%
3.1%
净利率更高
DOC
高出45.6%
27.6%
两年增速更快
DOC
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $1.4B |
| 净利润 | $114.0M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 17.4% | 34.6% |
| 净利率 | 73.2% | 27.6% |
| 营收同比 | 3.1% | 11.0% |
| 净利润同比 | 2406.4% | 13.9% |
| 每股收益（稀释后） | $0.16 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.4B | ||
| Q4 25 | $719.4M | $1.4B | ||
| Q3 25 | $705.9M | $1.3B | ||
| Q2 25 | $694.3M | $1.3B | ||
| Q1 25 | $702.9M | $1.3B | ||
| Q4 24 | $698.0M | $1.3B | ||
| Q3 24 | $700.4M | $1.2B |
净利润DOCRMD
| Q2 26 | — | $392.6M | ||
| Q1 26 | — | $398.7M | ||
| Q4 25 | $114.0M | $392.6M | ||
| Q3 25 | $-117.1M | $348.5M | ||
| Q2 25 | $31.7M | $379.7M | ||
| Q1 25 | $42.8M | $365.0M | ||
| Q4 24 | $4.5M | $344.6M | ||
| Q3 24 | $85.9M | $311.4M |
毛利率DOCRMD
| Q2 26 | — | 61.8% | ||
| Q1 26 | — | 62.2% | ||
| Q4 25 | — | 61.8% | ||
| Q3 25 | 58.6% | 61.5% | ||
| Q2 25 | 60.2% | 60.8% | ||
| Q1 25 | 61.1% | 59.3% | ||
| Q4 24 | 60.3% | 58.6% | ||
| Q3 24 | 60.0% | 58.6% |
营业利润率DOCRMD
| Q2 26 | — | 34.6% | ||
| Q1 26 | — | 34.9% | ||
| Q4 25 | 17.4% | 34.6% | ||
| Q3 25 | 9.2% | 33.4% | ||
| Q2 25 | 5.7% | 33.7% | ||
| Q1 25 | 7.7% | 33.0% | ||
| Q4 24 | -2.2% | 32.5% | ||
| Q3 24 | 14.1% | 31.6% |
净利率DOCRMD
| Q2 26 | — | 27.6% | ||
| Q1 26 | — | 27.9% | ||
| Q4 25 | 73.2% | 27.6% | ||
| Q3 25 | -16.6% | 26.1% | ||
| Q2 25 | 4.6% | 28.2% | ||
| Q1 25 | 6.1% | 28.3% | ||
| Q4 24 | 0.7% | 26.9% | ||
| Q3 24 | 12.3% | 25.4% |
每股收益（稀释后）DOCRMD
| Q2 26 | — | $2.68 | ||
| Q1 26 | — | $2.74 | ||
| Q4 25 | $0.16 | $2.68 | ||
| Q3 25 | $-0.17 | $2.37 | ||
| Q2 25 | $0.05 | $2.58 | ||
| Q1 25 | $0.06 | $2.48 | ||
| Q4 24 | $0.02 | $2.34 | ||
| Q3 24 | $0.12 | $2.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $1.4B |
| 总债务越低越好 | $9.8B | $663.8M |
| 股东权益账面价值 | $7.5B | $6.3B |
| 总资产 | $20.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.31× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资DOCRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.7B | ||
| Q4 25 | $467.5M | $1.4B | ||
| Q3 25 | $91.0M | $1.4B | ||
| Q2 25 | $89.4M | $1.2B | ||
| Q1 25 | $70.6M | $932.7M | ||
| Q4 24 | $119.8M | $521.9M | ||
| Q3 24 | $180.4M | $426.4M |
总债务DOCRMD
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | $664.1M | ||
| Q4 25 | $9.8B | $403.9M | ||
| Q3 25 | $9.1B | $408.7M | ||
| Q2 25 | $9.0B | $658.4M | ||
| Q1 25 | $8.9B | $663.1M | ||
| Q4 24 | $8.7B | $662.9M | ||
| Q3 24 | $8.6B | $667.6M |
股东权益DOCRMD
| Q2 26 | — | $6.3B | ||
| Q1 26 | — | $6.5B | ||
| Q4 25 | $7.5B | $6.3B | ||
| Q3 25 | $7.6B | $6.1B | ||
| Q2 25 | $7.9B | $6.0B | ||
| Q1 25 | $8.2B | $5.5B | ||
| Q4 24 | $8.4B | $5.3B | ||
| Q3 24 | $8.6B | $5.2B |
总资产DOCRMD
| Q2 26 | — | $8.5B | ||
| Q1 26 | — | $8.8B | ||
| Q4 25 | $20.3B | $8.5B | ||
| Q3 25 | $19.6B | $8.3B | ||
| Q2 25 | $19.8B | $8.2B | ||
| Q1 25 | $19.8B | $7.6B | ||
| Q4 24 | $19.9B | $7.1B | ||
| Q3 24 | $20.0B | $7.2B |
负债/权益比DOCRMD
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | 0.10× | ||
| Q4 25 | 1.31× | 0.06× | ||
| Q3 25 | 1.20× | 0.07× | ||
| Q2 25 | 1.14× | 0.11× | ||
| Q1 25 | 1.08× | 0.12× | ||
| Q4 24 | 1.04× | 0.13× | ||
| Q3 24 | 1.00× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | — |
| 自由现金流经营现金流 - 资本支出 | $357.0M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 124.4% | — |
| 现金转化率经营现金流/净利润 | 10.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $339.7M | ||
| Q3 25 | $315.0M | $457.3M | ||
| Q2 25 | $363.5M | $538.8M | ||
| Q1 25 | $279.4M | $578.7M | ||
| Q4 24 | $1.1B | $308.6M | ||
| Q3 24 | $318.2M | $325.5M |
自由现金流DOCRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $357.0M | $311.2M | ||
| Q3 25 | — | $414.4M | ||
| Q2 25 | — | $508.2M | ||
| Q1 25 | — | $557.9M | ||
| Q4 24 | $333.7M | $288.0M | ||
| Q3 24 | — | $307.7M |
自由现金流率DOCRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 49.6% | 21.9% | ||
| Q3 25 | — | 31.0% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | 47.8% | 22.5% | ||
| Q3 24 | — | 25.1% |
资本支出强度DOCRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 124.4% | 2.0% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | 105.6% | 1.6% | ||
| Q3 24 | — | 1.5% |
现金转化率DOCRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 10.99× | 0.87× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | 11.48× | 1.42× | ||
| Q1 25 | 6.52× | 1.59× | ||
| Q4 24 | 235.43× | 0.90× | ||
| Q3 24 | 3.71× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
